However, we did not study the impact of ERK1/2 inactivation in our FGFR3‐dependent bladder tumor models and we cannot, therefore, rule out the possible involvement of this pathway in cooperation with the AKT pathway, as shown for RAS (Sears et al, 2000; Yeh et al, 2004). Here, FGFR3 is linked to urinary bladder neoplasm.